These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1732425)

  • 1. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
    Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Pizzuto F; Hoskins W
    J Clin Oncol; 1992 Feb; 10(2):243-8. PubMed ID: 1732425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide and mesna in epithelial ovarian carcinoma.
    Sutton G
    Gynecol Oncol; 1993 Oct; 51(1):104-8. PubMed ID: 8244163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A; Crespo C; García-López JL; Pedraza M; Garrido P; Lastra E; Moyano A
    Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
    Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
    Sørensen P; Pfeiffer P; Bertelsen K
    Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
    J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S; Tognoni A; Pastrone I; Tomasello L; Brema F; Di Costanzo G; Folco U; Pronzato P;
    Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
    Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
    Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy.
    Scarfone G; Villa A; Parazzini F; Sciatta C; Polverino G; Bolis G
    Tumori; 1999; 85(4):217-9. PubMed ID: 10587020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; Malfetano JH
    Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
    Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
    J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.